Biotechnology company Engitix Ltd announced on Tuesday that it has elected Mike Burbridge, PhD in Pharmacology, as vice president of its Oncology & Immuno-oncology.
Dr Burbridge said he will support the progression of the company's programmes as well as work with the talented team to fulfil its ambition to support the development of new therapeutic options for patients with advanced chronic liver diseases and solid tumours.
Most recently, Dr Burbridge was programme director of External Innovation, director of oncology Translational and Clinical Research as well as clinical project director at Servier Centre for Therapeutic Innovation in Oncology,
Engitix added that Dr Burbridge brings over 20 years' experience in oncology drug discovery, translational research and clinical development to the company.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study